[go: up one dir, main page]

MX2024004195A - Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. - Google Patents

Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.

Info

Publication number
MX2024004195A
MX2024004195A MX2024004195A MX2024004195A MX2024004195A MX 2024004195 A MX2024004195 A MX 2024004195A MX 2024004195 A MX2024004195 A MX 2024004195A MX 2024004195 A MX2024004195 A MX 2024004195A MX 2024004195 A MX2024004195 A MX 2024004195A
Authority
MX
Mexico
Prior art keywords
activation system
contact activation
diseases associated
system associated
present
Prior art date
Application number
MX2024004195A
Other languages
English (en)
Inventor
Malini Viswanathan
Ryan Faucette
Daniel J Sexton
Tripti Gaur
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2024004195A publication Critical patent/MX2024004195A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Diabetes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En la presente se proporcionan los agentes de unión, los métodos y kits para analizar una muestra biológica obtenida de un sujeto que tenga, se sospeche de tener, o que esté en riesgo de una enfermedad asociada con el sistema de activación por contacto. En una modalidad preferida de la presente invención, la enfermedad asociada con el sistema de activación por contacto es angioedema hereditario (HAE), en otras modalidades de la presente invención, tal angioedema hereditario puede ser tipo I o tipo II. En una modalidad de la presente invención se divulga un método para identificar un método de tratamiento adecuado para un sujeto que tenga, se sospeche de tener, o que esté en riesgo de una enfermedad asociada con el sistema de activación por contacto, así como un método para evaluar la eficacia del tratamiento.
MX2024004195A 2016-09-16 2019-03-13 Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto. MX2024004195A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395770P 2016-09-16 2016-09-16
US201762518367P 2017-06-12 2017-06-12

Publications (1)

Publication Number Publication Date
MX2024004195A true MX2024004195A (es) 2024-04-23

Family

ID=59974882

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019002918A MX2019002918A (es) 2016-09-16 2017-09-15 Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
MX2024004195A MX2024004195A (es) 2016-09-16 2019-03-13 Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2019002918A MX2019002918A (es) 2016-09-16 2017-09-15 Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.

Country Status (13)

Country Link
US (3) US11340237B2 (es)
EP (1) EP3513197A1 (es)
JP (4) JP7225090B2 (es)
KR (3) KR20250030022A (es)
CN (2) CN109716137B (es)
AU (2) AU2017325986B2 (es)
BR (1) BR112019005167A2 (es)
CA (1) CA3037157A1 (es)
CO (1) CO2019002607A2 (es)
IL (2) IL265199B2 (es)
MX (2) MX2019002918A (es)
NZ (1) NZ792393A (es)
WO (1) WO2018053247A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011085103A2 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
KR102903403B1 (ko) * 2014-01-21 2025-12-24 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도
JP6719384B2 (ja) 2014-03-27 2020-07-15 ダイアックス コーポレーション 糖尿病黄斑浮腫の治療のための組成物および方法
CA3037154A1 (en) 2016-09-16 2018-03-22 Dyax Corp. Protein biomarkers for diseases associated with the contact activation system
BR112019005167A2 (pt) 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
EP3521828A1 (en) * 2018-01-31 2019-08-07 Centogene AG Method for the diagnosis of hereditary angioedema
EP3999846A4 (en) 2019-07-25 2023-08-09 Overture Life, Inc IDENTIFICATION OF VIABLE HUMAN EMBRYO
CN110514772A (zh) * 2019-08-09 2019-11-29 中国医学科学院基础医学研究所 透明肾细胞癌代谢标志物在肾细胞癌早期筛查和诊断产品中的应用
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021202948A2 (en) * 2020-04-04 2021-10-07 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
CN113495137A (zh) * 2021-06-29 2021-10-12 江苏省中医院 两种代谢标志物单独或联合在制备诊断克罗恩病的试剂盒中的应用
CN117310059B (zh) * 2023-11-30 2024-02-02 中国人民解放军总医院 用于早期诊断或监测克罗恩病的血浆代谢标志物组合及应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69533472T2 (de) 1994-01-11 2006-01-12 Dyax Corp., Cambridge Kallikreinhemmende "kunitz-domäne"-proteine und derivaten davon
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
DK2298278T3 (en) 2002-06-07 2016-02-01 Dyax Corp Prevention and reduction of blood loss and inflammatory response
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2005075662A2 (en) 2004-01-28 2005-08-18 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 2 (klk2)
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
BRPI0617332A2 (pt) 2005-10-11 2011-07-26 Tethys Bioscience Inc marcadores asoociados ao diabetes e mÉtodos de uso dos mesmos
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
EP2051707B1 (en) * 2006-07-31 2013-07-17 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2069778A2 (en) 2006-08-03 2009-06-17 Numira Biosciences, Inc. Methods and compositions for identifying biomarkers
ATE552503T1 (de) 2006-10-16 2012-04-15 Bayer Pharma AG Ctgf als biomarker, therapeutisches und diagnostisches ziel
EP2102357B1 (en) 2006-10-16 2013-11-27 Bayer Intellectual Property GmbH Ltbp2 as a biomarker, therapeutic and diagnostic target
EP2087359A1 (en) 2006-10-16 2009-08-12 Bayer Schering Pharma AG Prss23 as a biomarker, therapeutic and diagnostic target
WO2008046508A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Tgfb2 as a biomarker, therapeutic and diagnostic target
EP2118135A1 (en) 2006-10-16 2009-11-18 Bayer Schering Pharma AG Crtac as a biomarker, therapeutic and diagnostic target
WO2008046510A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Fn1 as a biomarker, therapeutic and diagnostic target
WO2008046528A1 (en) 2006-10-16 2008-04-24 Bayer Healthcare Ag Npr3 as a biomarker, therapeutic and diagnostic target
FR2914066B1 (fr) 2007-03-20 2009-05-22 Polyintell Sarl Kit d'analyse comprenant au moins deux polymeres a empreintes moleculaires et au moins un marqueur, ainsi que le procede d'analyse l'utilisant
PL2281204T3 (pl) 2008-04-29 2014-06-30 Psychemedics Corp Wieloanalitowa analiza w fazie stałej dla nadużywanych narkotyków i ich metabolitów
WO2010045180A1 (en) * 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
US8951739B2 (en) * 2009-08-12 2015-02-10 Human Metabolome Technologies Inc. Biomarker for depression, method for measuring a biomarker for depression, computer program, and recording medium
US20110098993A1 (en) 2009-10-27 2011-04-28 Anaxomics Biotech Sl. Methods and systems for identifying molecules or processes of biological interest by using knowledge discovery in biological data
BR112012010108A2 (pt) * 2009-10-30 2016-05-31 Prometheus Laboratoires Inc métodos para auxiliar no diagnóstico e para monitorar a progressão ou regressão da síndrome do intestino irritável, meio legível por computador, e, sistema para classificar se uma amostra de soro ou sangue de um indivíduo está associada com a síndrome do intestino irritável
ES2532006T3 (es) * 2009-11-20 2015-03-23 Pharnext Nuevas herramientas de diagnóstico para la enfermedad de Charcot-Marie-Tooth
WO2011085103A2 (en) 2010-01-06 2011-07-14 Dyax Corp. Plasma kallikrein binding proteins
JP2013522652A (ja) 2010-03-23 2013-06-13 パーデュー・リサーチ・ファウンデーション 代謝物プロファイリングを用いた再発乳癌の早期検出
US20120040383A1 (en) 2010-08-12 2012-02-16 Wei Jia Methods and Kits Relating To Metabolite Biomarkers For Colorectal Cancer
CN105713092B (zh) 2011-01-06 2019-09-10 戴埃克斯有限公司 血浆前激肽释放酶结合蛋白
JP5986440B2 (ja) * 2012-07-05 2016-09-06 国立医薬品食品衛生研究所長 アルツハイマー病の発症を予測する方法
CN104768560A (zh) 2012-08-29 2015-07-08 加州理工学院 孤独症谱系障碍的诊断和治疗
US20140086825A1 (en) * 2012-09-24 2014-03-27 William J. McFaul Methods and kits for assessing, modulating and treating substances affecting bodily processes
EP2948479B1 (en) 2013-01-20 2018-08-01 Dyax Corp. Evaluation and treatment of bradykinin-mediated disorders
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
CN105228623A (zh) 2013-03-14 2016-01-06 夏尔人类遗传性治疗公司 治疗b2-缓激肽受体介导的血管性水肿的方法
ES2683329T3 (es) * 2013-03-15 2018-09-26 Intrexon Corporation Diacilhidrazinas que contienen boro
JP6757252B2 (ja) 2013-10-21 2020-09-16 ダイアックス コーポレーション 血漿カリクレイン系バイオマーカーを決定するためのアッセイ
EP2884282A1 (en) * 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
EP3129909B1 (en) * 2014-04-08 2020-09-16 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
AU2015321470B2 (en) 2014-09-22 2018-11-15 National Health Research Institutes Use of 5-methoxytryptophan as diagnostic agent of inflammatory diseases
US20180298110A1 (en) * 2015-03-30 2018-10-18 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for preventing hereditary angioedema attack
IL311909B1 (en) 2015-08-13 2025-11-01 Takeda Pharmaceuticals Co Method for assesing the level of drug targeting the contact system in a subject
JP6570472B2 (ja) 2016-03-30 2019-09-04 株式会社マンダム 毛髪の損傷の評価方法
BR112019005167A2 (pt) 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
BR112019005172A2 (pt) 2016-09-16 2019-07-02 Dyax Corp. método e kit para analisar uma amostra
CA3037154A1 (en) 2016-09-16 2018-03-22 Dyax Corp. Protein biomarkers for diseases associated with the contact activation system

Also Published As

Publication number Publication date
CN109716137A (zh) 2019-05-03
US11340237B2 (en) 2022-05-24
WO2018053247A1 (en) 2018-03-22
MX2019002918A (es) 2019-07-18
EP3513197A1 (en) 2019-07-24
US20220365101A1 (en) 2022-11-17
JP7451791B2 (ja) 2024-03-18
KR20250030022A (ko) 2025-03-05
JP7225090B2 (ja) 2023-02-20
BR112019005167A2 (pt) 2019-07-02
KR102464380B1 (ko) 2022-11-07
US20190361036A1 (en) 2019-11-28
KR20220154245A (ko) 2022-11-21
AU2017325986B2 (en) 2023-12-14
CO2019002607A2 (es) 2019-03-29
NZ792393A (en) 2026-01-30
AU2017325986A1 (en) 2019-04-04
JP7692508B2 (ja) 2025-06-13
KR102775437B1 (ko) 2025-03-05
JP2024059990A (ja) 2024-05-01
IL265199B1 (en) 2024-09-01
CN109716137B (zh) 2023-07-21
JP2023058612A (ja) 2023-04-25
US12188948B2 (en) 2025-01-07
IL265199A (en) 2019-05-30
AU2024200561B2 (en) 2026-01-22
JP2019534446A (ja) 2019-11-28
JP2025124816A (ja) 2025-08-26
KR20190053914A (ko) 2019-05-20
US20250199014A1 (en) 2025-06-19
CA3037157A1 (en) 2018-03-22
NZ751481A (en) 2024-02-23
AU2024200561A1 (en) 2024-02-15
CN117169508A (zh) 2023-12-05
IL314752A (en) 2024-10-01
IL265199B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
MX2024004195A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
CO2019002608A2 (es) Biomarcadores de arn para angioedema hereditario
MX2019010958A (es) Metodos de tratamiento de tumores.
MX2017015461A (es) Métodos para diagnosticar y tratar el cáncer.
MX2020001575A (es) Materiales y métodos para evaluar y tratar el cáncer.
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
EA201400491A1 (ru) Сопровождающая диагностика для терапии с антигиалуроновым агентом и способы ее применения
MX2017011486A (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
BR112014031365A2 (pt) métodos de detectar doenças ou condições
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX341517B (es) Biomarcadores de cancer pancreatico y usos de los mismos.
MX2016016742A (es) Ceramidas y su uso en el diagnostico de enfermedad cardiovascular (ecv).
MX2018013621A (es) Metodo, matriz y uso de estos.
BR112016002845A2 (pt) composições e métodos para tratar condições associadas ao complemento
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
MX2025004103A (es) Metodos de identificacion de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
CL2020001936A1 (es) Métodos para el tratamiento de la atrofía muscular espinal.
MX2021007951A (es) Ensayo multiplexado y metodos de uso del mismo.
MX2017006075A (es) Biomarcadores para la progresion de enfermedades en melanoma.
MX374415B (es) Composiciones y métodos para identificar un riesgo de cáncer en un sujeto.
MX2022001898A (es) Metodos para el tratamiento de enfermedades asociadas a la senescencia.
MX2018011679A (es) Biomarcadores de proteopatias y usos de los mismos.
EA201891170A1 (ru) Биомаркер поликистозной болезни почек и варианты его применения
MX2021009987A (es) Metodos para el etiquetado de celulas eucariotas de un organismo multicelular utilizando compuestos monosacaridos modificados.